nach oben

European Journal of Clinical Microbiology & Infectious Diseases

27.04.2024 | Brief Report

Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit

verfasst von: Emmanuel Dudoignon, Francois Caméléna, Matthieu Lafaurie, Benjamin Deniau, Maité Chaussard, Maxime Coutrot, Lucie Guillemet, Alexandru Cupaciu, Alexandre Pharaboz, Louis Boutin, Mourad Benyamina, Marc Chaouat, Maurice Mimoun, Manel Merimèche, Alexandre Mebazaa, Benoit Plaud, Béatrice Berçot, François Dépret, Guillaume Mellon

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases

Einloggen, um Zugang zu erhalten

Summary

We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry bla_OXA−23 and armA resistance genes. Despite the lack of clinical cure, all five infected patients survived and were discharged from the Burn Intensive Care Unit.

Nur mit Berechtigung zugänglich

Teng J, Imani S, Zhou A, Zhao Y, Du L, Deng S et al (2023) Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother Biomedecine Pharmacother 167:115564. https://doi.org/10.1016/j.biopha.2023.115564CrossRef

Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL et al (2019) Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis IJID off Publ Int Soc Infect Dis 79:179–184. https://doi.org/10.1016/j.ijid.2018.11.371CrossRef

Corcione S, Lupia T, De Rosa FG, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2020) Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma 8:tkaa033. https://doi.org/10.1093/burnst/tkaa033CrossRefPubMedPubMedCentral

Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379–1391. https://doi.org/10.1093/jac/dkab015CrossRefPubMed

Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9CrossRefPubMed

Mellon G, Clec’h C, Picard B, Cohen Y, Jauréguy F (2012) Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 18(6):958–960. https://doi.org/10.1007/s10156-012-0404-9CrossRefPubMed

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A new twist: the combination of Sulbactam/Avibactam enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) isolates. Antibiot (Basel) 10(5):577. https://doi.org/10.3390/antibiotics10050577CrossRef

Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP et al (1985) The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 121(2):182–205. https://doi.org/10.1093/oxfordjournals.aje.a113990CrossRefPubMed

Smoke SM, Brophy A, Reveron S, Iovleva A, Kline EG, Marano M et al (2023) Evolution and transmission of Cefiderocol-Resistant Acinetobacter baumannii during an outbreak in the burn Intensive Care Unit. Clin Infect Dis off Publ Infect Dis Soc Am 76(3):e1261–e1265. https://doi.org/10.1093/cid/ciac647CrossRef

10.

Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J et al (2023) Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter Baumannii among patients from different global regions Clin Infect Dis. https://doi.org/10.1093/cid/ciad556

11.

Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025CrossRef

12.

Gill CM, Santini D, Takemura M, Longshaw C, Yamano Y, Echols R et al (2023 Apr) In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkad032

13.

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel). May https://doi.org/10.3390/antibiotics10050577

14.

Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A (2020 Jul) In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. https://doi.org/10.1099/jmm.0.001211

15.

Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfo V, Limongi F et al (June 2023) Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization. JAC-Antimicrobial Resist 5. https://doi.org/10.1093/jacamr/dlad078

Titel: Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit
verfasst von: Emmanuel Dudoignon
Francois Caméléna
Matthieu Lafaurie
Benjamin Deniau
Maité Chaussard
Maxime Coutrot
Lucie Guillemet
Alexandru Cupaciu
Alexandre Pharaboz
Louis Boutin
Mourad Benyamina
Marc Chaouat
Maurice Mimoun
Manel Merimèche
Alexandre Mebazaa
Benoit Plaud
Béatrice Berçot
François Dépret
Guillaume Mellon
Publikationsdatum: 27.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-024-04840-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Innere Medizin